TYMS and lung carcinoma: That is, activated nucleotide metabolism promoted gefitinib resistance in lung cancer, whereas pemetrexed impaired cellular nucleotide metabolism through inhibition of TS, thereby diminishing the cell proliferation and further re‐sensitising the resistant cells to gefitinib.